新型冠状病毒肺炎对肠道微生物群及肠黏膜屏障缺陷影响机制的研究进展

doi:10.11958/20220608

天津医药 ›› 2023, Vol. 51 ›› Issue (1): 105-108.doi: 10.11958/20220608

新型冠状病毒肺炎对肠道微生物群及肠黏膜屏障缺陷影响机制的研究进展

孙强(), 宋维亮()

天津医科大学三中心临床学院、天津市第三中心医院普外科，天津市重症疾病体外生命支持重点实验室，天津市人工细胞工程技术研究中心，天津市肝胆疾病研究所（邮编300170）

收稿日期:2022-04-22 修回日期:2022-07-07 出版日期:2023-01-15 发布日期:2023-01-17
通讯作者: 宋维亮 E-mail:Eliza1977@163.com;13502028601@163.com
作者简介:孙强（1972），男，主治医师，主要从事胃肠道肿瘤方面研究。E-mail：Eliza1977@163.com

Research progress of influencing mechanism of COVID-19 on intestinal microbiota and related intestinal mucosal barrier defects

SUN Qiang(), SONG Weiliang()

Department of General Surgery, the Third Central Clinical College of Tianjin Medical University, Tianjin Third Central Hospital Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Institute of Hepatobiliary Disease, Tianjin 300170, China

Received:2022-04-22 Revised:2022-07-07 Published:2023-01-15 Online:2023-01-17
Contact: SONG Weiliang E-mail:Eliza1977@163.com;13502028601@163.com

孙强, 宋维亮. 新型冠状病毒肺炎对肠道微生物群及肠黏膜屏障缺陷影响机制的研究进展[J]. 天津医药, 2023, 51(1): 105-108.

SUN Qiang, SONG Weiliang. Research progress of influencing mechanism of COVID-19 on intestinal microbiota and related intestinal mucosal barrier defects[J]. Tianjin Medical Journal, 2023, 51(1): 105-108.

摘要/Abstract

摘要：

肠道微生物群与肠黏膜屏障之间的交互作用对维持肠道内环境的稳定起到了至关重要的作用。新型冠状病毒感染可以通过不同方式直接或间接破坏肠道微生物群的多样性，影响肠黏膜屏障的结构与代谢。肠道内稳态与微环境在新型冠状病毒肺炎（COVID-19）的发病机制及全身炎症反应的增强中至关重要，提示肠道微生物群及黏膜屏障可作为逆转该类患者病理进程重要的治疗靶点。就COVID-19所致肠道微生物群及相关肠黏膜屏障缺陷机制的研究进展进行综述。

关键词: 胃肠道微生物组, 肠黏膜屏障, 呼吸综合征冠状病毒2, 新型冠状病毒肺炎, 全身炎症反应, 肠道内稳态与微环境

Abstract:

The interaction between intestinal microbiota and intestinal mucosal barrier plays an important role in maintaining the stability of intestinal environment. Respiratory syndrome coronavirus infection can directly or indirectly disrupt the diversity of intestinal microflora through different ways, and affect the structure and metabolism of intestinal mucosal barrier. The intestinal homeostasis and microenvironment appear to play a major role in the pathogenesis of coronavirus disease 2019 (COVID-19) and the enhancement of the systemic inflammatory responses, suggesting that intestinal microbiota and mucosal barrier can be used as important therapeutic targets to reverse the pathological process of these patients. Therefore, this paper is a review about the research progress on the mechanism of COVID-19 induced intestinal microbiota and related intestinal mucosal barrier defects.

Key words: gastrointestinal microbiome, intestinal mucosal barrier, respiratory syndrome coronavirus 2, coronavirus disease 2019, systemic inflammatory responses, intestinal homeostasis and microenvironment

中图分类号:

R512.5，R373.1

参考文献 37

[1]	VISCO V, V ITALE C, RISPOLI A, et al. Post-COVID-19 syndrome:involvement and interactions between respiratory,cardiovascular and nervous systems[J]. J Clin Med, 2022, 11(3):524-539. doi:10.3390/jcm11030524.
[2]	WU L H, YE Z N, PENG P, et al. Efficacy and safety of washed microbiota transplantation to treat patients with mild-to-severe COVID-19 and suspected of having gut microbiota dysbiosis:Study protocol for a randomized controlled trial[J]. Curr Med Sci, 2021, 41(6):1087-1095. doi:10.1007/s11596-021-2475-2.
[3]	GAEBLER C, WANG Z, LORENZI J C C, et al. Evolution of antibody immunity to SARS-CoV-2[J]. Nature, 2021, 591(7851):639-644. doi:10.1038/s41586-021-03207-w.
[4]	RIEDEL S, PHEIFFER C, JOHNSON R, et al. Intestinal barrier function and immune homeostasis are missing links in obesity and type 2 diabetes development[J]. Front Endocrinol (Lausanne),2021, 12(2):833544. doi:10.3389/fendo.2021.833544.
[5]	RUTSCH A, KANTSJÖ J B, RONCHI F, et al. The gut-brain axis:How microbiota and host inflammasome influence brain physiology and pathology[J]. Front Immunol, 2020, 11(10):604179. doi:10.3389/fimmu.2020.604179.
[6]	LEWIS C V, TAYLOR W R. Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease[J]. Am J Physiol Heart Circ Physiol, 2020, 319(6):H1227-H1233. doi:10.1152/ajpheart.00612.2020.
[7]	BURBERRY A, WELLS M F, LIMONE F, et al. C9orf72 suppresses systemic and neural inflammation induced by gut bacteria[J]. Nature, 2020, 582(7810):89-94. doi:10.1038/s41586-020-2288-7.
[8]	BRANISTE V, AI-ASMAKH M, KOWAL C, et al. The gut microbiota influences blood-brain barrier permeability in mice[J]. Sci Transl Med, 2014, 6(263):263ra158. doi:10.1126/scitranslmed.3009759.
[9]	SANDEK A, SWIDSINSKI A, SCHROEDL W, et al. Intestinal blood flow in patients with chronic heart failure:a link with bacterial growth,gastrointestinal symptoms,and cachexia[J]. J Am Coll Cardiol, 2014, 64(11):1092-1102. doi:10.1016/j.jacc.2014.06.1179.
[10]	ZHOU X, LI J, GUO J, et al. Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction[J]. Microbiome, 2018, 6(1):66-82. doi:10.1186/s40168-018-0441-4.
[11]	SIWCZAK F, LOFFET E, KAMINSKA M, et al. Intestinal stem cell-on-chip to study human host-microbiota interaction[J]. Front Immunol, 2021, 12(6):798552. doi:10.3389/fimmu.2021.798552.
[12]	ALLAM-NDOUL B, CASTONGUAY-PARADIS S, VEILLEUX A. Gut microbiota and intestinal trans-epithelial permeability[J]. Int J Mol Sci, 2020, 21(17):6402-6413. doi:10.3390/ijms21176402.
[13]	HAN X, LEE A, HUANG S, et al. Lactobacillus Rhamnosus GG prevents epithelial barrier dysfunction induced by interferon-gamma and fecal supernatants from irritable bowel syndrome patients in human intestinal enteroids and colonoids[J]. Gut Microbes, 2019, 10(3):59-76. doi:10.1080/19490976.2018.1479625.
[14]	HU Z, ZHANG C, SIFUENTES-DOMINGUEZ L, et al. Small proline-rich protein 2A is a gut bactericidal protein deployed during helminth infction[J]. Science, 2021, 374(18):eabe6723. doi:10.1126/science.abe6723.
[15]	ZUO T, ZHANG F, LUI G C Y, et al. Alterations in gut micro‐ biota of patients with COVID-19 during time of hospitalization[J]. Gastroenterology, 2020, 159(3):944-955. doi:10.1053/j.gastro.2020.05.048.
[16]	ZUO T, ZHAN H, ZHANG F, et al. Alterations in fecal fungal microbiome of patients with COVID-19 during time of hospitalization until discharge[J]. Gastroenterilogy, 2020, 159(4):1302-1310. doi:10.1053/j.gastro.2020.06.048.
[17]	REN Z, WANG H, CUI G, et al. Alterations in the human oral and gut microbiomes and lipidomics in COVID‐19[J]. Gut, 2021, 70(7):1253-1265. doi:10.1136/gutjnl-2020-323826.
[18]	ZUO T, LIU Q, ZHANG F, et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19[J]. Gut, 2021, 70(2):276-284. doi:10.1136/gutjnl-2020-322294.
[19]	LIU Y, KUANG D, LI D, et al. Roles of the gut microbiota in severe SARS-CoV-2 infection[J]. Cytokine Growth Factor Rev, 2022, 63(2):98-107. doi:10.1016/j.cytogfr.2022.01.007.
[20]	HOFFMANN M, WEBER H K, SCHROEDER S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2):271-280. doi:10.1016/j.celll.2020.02.052.
[21]	CHEN L, LI X, CHEN M, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2[J]. Cardiovasc Res, 2020, 116(6):1097-1100. doi:10.1093/cvr/cvaa078.
[22]	HASHINOTO T, PERIOT T, REHMAN A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation[J]. Nature, 2012, 487(7408):477-481. doi:10.1038/nature11228.
[23]	YANG T, CHATRABORTY S, SAHA P, et al. Gnotobiotic rats reveal that gut microbiota regulates colonic mRNA of ACE2,the receptor for SARS-CoV-2 infectivity[J]. Hypertension, 2020, 76(1):e1-e3. doi:10.1161/HYPERTENSIONAHA.120.15360.
[24]	WU C M, CHEN X Y, CAI Y P, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with conronavirus disease 2019 pneumonia in Wuhan,China[J]. JAMA Intern Med,2020, 180(7):934-943. doi:10.1001/jamaintermed.2020.0994.
[25]	NEURATH M F. COVID-19 and immunomodulation in IBD[J]. Gut, 2020, 69(7):1335-1342. doi:10.1136/gutjnl-2020-321269.
[26]	ZHANG F, MEARS J R, SHAKIB L, et al. IFN-γ and TNF-α drive a CXCL10⁺ CCL2⁺ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation[J]. Genome Med, 2021, 13(1):64-70. doi:10.1186/s13073-021-00881-3.
[27]	ZHANG X, SHI L, SUN T, et al. Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients[J]. BMC Microbiol, 2021, 21(1):78-86. doi:10.1086/s12866-021-02125-1.
[28]	BULANDA E, WYPYCH T P. Bypassing the gut-lung axis via microbial metabolites:implications for chronic respiratory diseases[J]. Front Microbiol, 2022, 13(4):857418. doi:10.3389/fmicb.2022.857418.
[29]	MELO-GONZÁLEZ F, SEPÚLVEDA-ALFARO J, SCHULTZ B M, et al. Distal consequences of mucosal infections in intestinal and lung inflammation[J]. Front Immunol, 2022, 13(3):877533. doi:10.3389/fimmu.2022.877533.
[30]	NAJMI N, MEGANTARA I, ANDRIANI L, et al. Importance of gut microbiome regulation for the prevention and recovery process after SARS-CoV-2 respiratory viral infection[J]. Biomed Rep, 2022, 16(4):25-30. doi:10.3892/br.2022.1508.
[31]	MULLISH B H, MARCHESI J R, MCDONALD J A K, et al. Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults:Should we be considering probiotics during viral pandemics?[J]. Gut Microbes, 2021, 13(1):1-9. doi:10.1080/19490976.2021.1900997.
[32]	YU W, OU X, LIU X, et al. ACE2 contributes to the maintenance of mouse epithelial barrier function[J]. Biochem Biophys Res Commun, 2020, 533(4):1276-1282. doi:10.1016/j.bbrc.2020.10.002.
[33]	ZHANG H, LI H B, LYU J R, et al. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection[J]. Int J Infect Dis, 2020, 96(18):19-24. doi:10.1016/j.ijid.2020.04.027.
[34]	CARVALHO A, ALQUSAIRI R, ADAMS A, et al. SARS-CoV-2 gastrointestinal infection causing hemorrhagic colitis:implications for detection and transmission of COVID-19 disease[J]. Am J Gastroenterol, 2020, 115(6):942-946. doi:10.14309/ajg.0000000000000667.
[35]	ROY K, AGARWAL S, BANERJEE R, et al. COVID-19 and gut immunomodulation[J]. World J Gastroenterol, 2021, 27(46):7925-7942. doi:10.3748/wjg.v27.i46.7925.
[36]	MALDONADO GALDEANO C, CAZORLA S I, LEMME DUMIT J M, et al. Beneficial effects of probiotic consumption on the immune system[J]. Ann Nutr Metab, 2019, 74(2):115-124. doi:10.1159/000496426.
[37]	WANG J, LI F, WEI H, et al. Respiratory influenza virus infection induces intestinal immune injury via microbiota mediated Th17 cell-dependent inflammation[J]. J Exp Med, 2014, 211(12):2397-2410. doi:10.1084/jem.20140625.

新型冠状病毒肺炎对肠道微生物群及肠黏膜屏障缺陷影响机制的研究进展

Research progress of influencing mechanism of COVID-19 on intestinal microbiota and related intestinal mucosal barrier defects

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 37

相关文章 15

编辑推荐

Metrics

本文评价

[1]	祁福敏, 苏睿, 郝剑, 苏丽, 范倩, 李昕, 魏蔚. 显微镜下多血管炎相关间质性肺病合并COVID-19患者疫苗保护作用初探[J]. 天津医药, 2024, 52(7): 683-686.
[2]	吕梦娜, 李建斌, 吴锐. 自身炎症性疾病患者合并COVID-19严重程度的早期预测指标探讨[J]. 天津医药, 2024, 52(5): 528-531.
[3]	张萌, 崔瑞洁, 李彩芳, 高琦, 李斐. 盐酸小檗碱片联合复方谷氨酰胺对溃疡性结肠炎患者肠黏膜屏障功能的影响[J]. 天津医药, 2024, 52(1): 102-106.
[4]	梁燕, 高静. 乳酸杆菌在急性心肌梗死防治中的潜在机制及应用进展[J]. 天津医药, 2024, 52(1): 107-112.
[5]	胡明月, 李鑫, 高磊, 关明杰. 蒙古黄芪皂苷对铅暴露致发育期大鼠神经炎症与肠道菌群紊乱的影响[J]. 天津医药, 2023, 51(9): 955-960.
[6]	谷松涛, 贾玮, 李月川, 张冬睿, 张雅婷, 高淑连, 李娜. COVID-19合并肺血栓栓塞症的临床特点[J]. 天津医药, 2023, 51(8): 873-877.
[7]	祝淑平, 马丽, 叶晓林, 顾俊菲. 妊娠期糖尿病患者不同孕期肠道微生物和代谢产物水平变化与胰岛素抵抗的关系[J]. 天津医药, 2023, 51(6): 624-627.
[8]	钟慕贤, 谢新荣. 糖尿病酮症酸中毒合并新型冠状病毒肺炎的临床特征分析[J]. 天津医药, 2023, 51(12): 1378-1381.
[9]	崔亚琼, 刘薇. 新型冠状病毒感染相关儿童多系统炎症综合征与细胞因子风暴[J]. 天津医药, 2022, 50(12): 1340-1344.
[10]	冯李婷, 王星, 李莉, 吴琦. 天津市输入型新型冠状病毒奥密克戎变异毒株感染者的临床特征分析[J]. 天津医药, 2022, 50(10): 1083-1087.
[11]	葛军涛, 詹江华△. 胆道闭锁Kasai术后辅助治疗研究进展[J]. 天津医药, 2022, 50(1): 30-34.
[12]	李亚丹 , 周子伟 , 吴迪 , 雷平 . 脑创伤治疗的新靶点：脑-肠轴[J]. 天津医药, 2021, 49(8): 887-891.
[13]	杨洁珂, 王丽, 于千惠, 刁会, 樊均明. 黄芪多糖对小鼠慢性肾功能衰竭保护作用的机制研究[J]. 天津医药, 2021, 49(7): 713-718.
[14]	赵以琳, 于琴, 周娟, 严骅. 妊娠期母体肠道微生态调节对子代影响的研究进展 #br#[J]. 天津医药, 2021, 49(6): 668-672.
[15]	郭晶, 李莉, 吴茜, 李红蔚, 史丽霞, 吴琦. 系统免疫炎症指数对新型冠状病毒肺炎核酸转阴时间的影响[J]. 天津医药, 2021, 49(11): 1188-1192.